Vorinostat Completed Phase 2 Trials for Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukemia (AML) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00656617Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)